AMBS is splitted in two separate companies - one for diagnostics (with Lympro end NuroPro) and one for Pharma (with Eltoprazine and MANF)
AMBS Diagnostic uplists easily to AMEX once Lympro is on the market
AMBS Pharma get the uplist to Nasdaq once there is a JV with Novartis or another BF (eventually with a R/S on strenght)
Exciting times ahead
That does it. I am officially done with this board until the autumn solstice. The idea of a spin-off is ridiculous. And the fact that the subject generates a conversation is enough for me to get lost. I know I won't be missed, as I rarely even post, but none the less, "Arrivederci!"
They will not uplist separately. If given the opportunity to uplist that will happen for the entire company in my opinion. Then they might at some point if it makes sense split into very different businesses.
Actually, that is a possibility! Who knows though. I think we should up list in the September through November range of this year. If we wait until next February or later, that would be a disappointment. Is Gerald ready to spin off the Diagnostic Division to us shareholders in the next few months, prior to up listing it? That would be bold. I don't know. I'd love it though. I think the Diagnostic Division is going to be a monster revenue machine!! I love the idea of having the same percentage of shares in two separate companies. From a risk stand point, I think that makes sense. Why subject LymPro's slam dunk growth to some potential lawsuit or failure in the Therapeutic Division? Let them stand separately! It will happen. The question is when?